CN104080474B - C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 - Google Patents

C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 Download PDF

Info

Publication number
CN104080474B
CN104080474B CN201280063159.7A CN201280063159A CN104080474B CN 104080474 B CN104080474 B CN 104080474B CN 201280063159 A CN201280063159 A CN 201280063159A CN 104080474 B CN104080474 B CN 104080474B
Authority
CN
China
Prior art keywords
edema
purposes
brain
secondary cases
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280063159.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104080474A (zh
Inventor
C·克莱因施尼茨
M·诺尔特
G·施托尔
G·迪克奈特
S·舒尔特
B·尼斯万特
I·普拉格斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CN104080474A publication Critical patent/CN104080474A/zh
Application granted granted Critical
Publication of CN104080474B publication Critical patent/CN104080474B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280063159.7A 2011-12-22 2012-12-21 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 Active CN104080474B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254 2011-12-22
EP11195254.5 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (2)

Publication Number Publication Date
CN104080474A CN104080474A (zh) 2014-10-01
CN104080474B true CN104080474B (zh) 2016-04-27

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280063159.7A Active CN104080474B (zh) 2011-12-22 2012-12-21 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用

Country Status (10)

Country Link
US (1) US9452203B2 (cg-RX-API-DMAC7.html)
EP (1) EP2793935B1 (cg-RX-API-DMAC7.html)
JP (1) JP6127063B2 (cg-RX-API-DMAC7.html)
KR (1) KR102022231B1 (cg-RX-API-DMAC7.html)
CN (1) CN104080474B (cg-RX-API-DMAC7.html)
AU (1) AU2012318275B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858984C (cg-RX-API-DMAC7.html)
DK (1) DK2793935T3 (cg-RX-API-DMAC7.html)
ES (1) ES2587863T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013093027A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
LT3290046T (lt) 2013-03-15 2019-03-12 Shire Viropharma Incorporated C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365478A (zh) * 2005-12-21 2009-02-11 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
KR101508668B1 (ko) 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365478A (zh) * 2005-12-21 2009-02-11 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation;Claudio Storini et al.;《Neurobiology of Disease》;20050221(第19期);第10-17页 *
Claudio Storini et al..C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation.《Neurobiology of Disease》.2005,(第19期),第10-17页. *
Protective effect of C1 esterase inhibitor on acute traumatic spinal cord injury in the rat;R. Tei et al.;《Neurological Research》;20080930;第30卷;第761-767页 *

Also Published As

Publication number Publication date
EP2793935A1 (en) 2014-10-29
HK1201729A1 (zh) 2015-09-11
AU2012318275A1 (en) 2013-07-11
CN104080474A (zh) 2014-10-01
KR20140107567A (ko) 2014-09-04
ES2587863T3 (es) 2016-10-27
US20140371425A1 (en) 2014-12-18
JP6127063B2 (ja) 2017-05-10
DK2793935T3 (en) 2016-09-05
JP2015502389A (ja) 2015-01-22
CA2858984C (en) 2021-01-05
EP2793935B1 (en) 2016-05-25
KR102022231B1 (ko) 2019-09-19
AU2012318275B2 (en) 2016-05-19
WO2013093027A1 (en) 2013-06-27
CA2858984A1 (en) 2013-06-27
US9452203B2 (en) 2016-09-27

Similar Documents

Publication Publication Date Title
CN104080474B (zh) C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
ES2392596T3 (es) Neurregulina en el tratamiento de enfermedades cardiacas
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
Salman et al. Acute hyperglycemia exacerbates hemorrhagic transformation after embolic stroke and reperfusion with tPA: a possible role of TXNIP-NLRP3 inflammasome
Sang et al. Early increased bradykinin 1 receptor contributes to hemorrhagic transformation after ischemic stroke in type 1 diabetic rats
US10772827B2 (en) Composition for treating apoplexy through nasal administration
Yuan et al. Inactivation of ERK1/2 signaling mediates dysfunction of basal meningeal lymphatic vessels in experimental subdural hematoma
US20080260644A1 (en) Chloride transport upregulation for the treatment of traumatic brain injury
Simats et al. Ceruletide and alpha-1 antitrypsin as a novel combination therapy for ischemic stroke
US20230108970A1 (en) Methods and compositions for improving kidney function in patients with hepatorenal syndrome
US20180207246A1 (en) Compositions and methods for treating post-operative complications of cardiopulmonary surgery
WO2012006585A2 (en) Use of interleukin-15 to treat cardiovascular diseases
US9974831B2 (en) Methods of reducing myocardial injury following myocardial infarction
US20200390872A1 (en) Treatment and prevention of pre-eclampsia
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
Martínez-Fernández et al. Edoxaban treatment in a post-infarction experimental model
US10441631B2 (en) Therapeutic agent for amniotic fluid embolism
US20250144179A1 (en) Peptide hormone to prevent or treat vasospasm, brain injury or cerebral edema
Hernaningsih et al. Sindroma Cushing Pada Kehamilan
Ranasinghe et al. An unusual presentation of idiopathic thrombocytopenic purpura in pregnancy
de Aguiar et al. Cerebral vasospasm following subarachnoid hemorrhage (SAH):: Physiopathology, diagnosis and current management. Critical review of literature
JP2007262027A (ja) Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤
CN114470196A (zh) CCL3/CCR4中和抗体、NF-κB抑制剂在制备NEC治疗药物中的用途
Grbavac et al. Prevention and Treatment of Ovarian Hyperstimulation Syndrome
Doyle Development of novel therapeutics for stroke: preclinical investigations of osteopontin and 3-iodothyronamine.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant